A Study to Evaluate the Effectiveness and Safety of Restylane Skinboosters Vital Lidocaine

This is a randomized, evaluator-blinded, no-treatment controlled, study to evaluate the effectiveness and safety of Restylane Skinboosters Vital Lidocaine treatment to improve skin quality of the face in China. Subjects of Chinese origin, age 18 years, who are eligible for treatment to improve skin quality of the face. Study center is up to 8. A total of approximately 171 subjects will be randomized (2:1) to either treatment with Restylane Skinboosters Vital Lidocaine Treatment Group (approximately 114 subjects) or no-treatment Control Group (approximately 57 subjects).

NCT Number	NCT07047638
Lead Sponsor	Galderma R&D
Conditions	Skin Quality Improvement
Enrollment	171 participants
Start Date	2025-07-09
Primary Completion	2026-04-28 (estimated)
Study Completion	2027-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-17